神经药理学研究关于pioglitazone在学习和记忆中的重新利用:一个与剂量相关的研究研究
- Huma Ikram1, - Rabia Masood1, - Shazia Syed2
1Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.
Pakistan journal of pharmaceutical sciences
|August 21, 2023
概括
抗糖尿病药物皮奥格利塔 (pioglitazone) 增强了记忆力,并在老鼠中显示出抗抑郁作用. 10mg/kg的剂量显著提高了记忆力和多巴胺代谢,表明了治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 代谢过程中的代谢.
背景情况:
- 皮奥格利塔是一种抗糖尿病药物.
- 新出现的证据表明,皮奥格利塔可能会改善认知功能.
- 皮奥格利塔对单胺代谢的影响及其治疗影响需要进一步研究.
研究的目的:
- 调查皮奥格利塔对记忆检索的剂量依赖作用.
- 为了检查皮奥格利塔对单胺代谢的影响.
- 为了评估pioglitazone的抗焦虑和抗抑郁性质.
主要方法:
- 给老鼠服用了三剂皮奥格利塔 (5,10,15mg/kg).
- 行为评估包括莫里斯水迷宫,斯金纳盒子,光暗活动盒,强迫游泳测试,升空加迷宫和开放场地测试.
- 用电化学检测 (HPLC-EC) 的高性能液体染色学量化生物氨基和代谢物.
主要成果:
- 皮奥格利塔在所有测试剂量中都表现出增强记忆的效果,在10mg/kg时观察到最佳的增强.
- 在接受皮奥格利塔治疗的老鼠中,观察到显著的抗焦虑和抗抑郁作用.
- 低剂量皮奥格利塔 (5mg/kg) 没有显著改变多巴胺代谢,而中等剂量 (10mg/kg) 显著增加了它.
结论:
- 皮奥格利塔具有剂量依赖的增强记忆,抗焦虑和抗抑郁作用.
- 药物对多巴胺代谢的影响是剂量依赖的,在10mg/kg时观察到显著增加.
- 这些发现可能会为pioglitazone在神经系统疾病 (包括帕金森病) 的治疗应用提供信息.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
01:06Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
152
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
152
01:23Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358